ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 049

What Happens After Juvenile Myositis Patients Screen Positive for Mental Health Comorbidities? Update from a Multicenter Juvenile Myositis Mental Health Screening Pilot Study

Kaveh Ardalan1, Rebecca Fillipo1, Christina ZIgler2, Audrey Ward1, Jeffrey Dvergsten3, Ann Reed1, Alison Manning1, Gary Maslow1, Brian Feldman4, Ashley Danguecan5, Sarah Mossad5, Luana Flores Pereira5, Susan Shenoi6, Stacey Haynes7, Joanna Patten7 and Andrea Knight5, 1Duke University School of Medicine, Durham, NC, 2Duke, Durham, NC, 3Duke University Hospital, Durham, NC, 4Hospital for Sick Children / University of Toronto, Toronto, ON, Canada, 5The Hospital for Sick Children, Toronto, ON, Canada, 6Seattle Children's Hospital, Seattle, WA, 7Seattle Childrens Hospital and Research Center / University of Washington, Seattle, WA

Meeting: 2023 Pediatric Rheumatology Symposium

Keywords: juvenile dermatomyositis, juvenile myositis, mental health, Pediatric rheumatology, quality of care

  • Tweet
  • Email
  • Print
Session Information

Date: Thursday, March 30, 2023

Title: Posters: Clinical and Therapeutic I

Session Type: Poster Session A

Session Time: 6:00PM-7:00PM

Background/Purpose: Juvenile myositis (JM) patients report high rates of emotional distress but qualitative studies suggest challenges accessing high quality mental health care. We present survey data on mental health specialist follow-up for JM patients who screened positive in a multicenter North American JM mental health screening pilot study.

Methods: JM patients/parents (5-21 yo) completed patient/parent-proxy mental health screeners (i.e. Pediatric Symptom Checklist-17 [PSC-17], Patient Health Questionnaire-9 [PHQ9], Screen for Child Anxiety Related Disorders [SCARED]). Demographic/clinical data and Patient-Reported Outcomes Measurement Information System (PROMIS) pediatric/parent-proxy mental health symptom intensity measures were collected. Patients with positive screening, defined as any total/domain scores above established clinical cutoffs, were referred for mental health specialist evaluation. Four weeks after referral, parents (or 18yo+ patients) were emailed surveys evaluating: 1) if they had seen a mental health specialist, 2) barriers to mental health evaluation, 3) facilitators for addressing mental health, and 4) satisfaction with mental health care. Barriers/facilitators were adapted from a prior Patients, Advocates, and Rheumatology Teams Network for Research and Service (PARTNERS) study and respondents could indicate presence/absence of as many as they liked. Descriptive statistics were calculated.

Results: Seventy-two participants enrolled, with 49 (68%) screening positive and 20 completing follow-up surveys (41% response rate). Most (n = 19) respondents were parents and survey responses were more often received for female patients with higher PROMIS physical function and lower PROMIS emotional distress scores, though responders/nonresponders were otherwise comparable (Table 1). Of the patients screening positive, most patients (n = 15, 75%) had not yet scheduled mental health specialist evaluation, 1 (5%) had scheduled but not attended, and 4 (20%) had visited a specialist with only 1 of these 4 reporting initiation of psychotropic medication. Barriers included difficulty finding nearby specialists who understand JM patients experiences (Figure 1). Facilitators, such as pediatric rheumatologists discussing mental health needs, are shown (Figure 2). A plurality felt mental health needs were being ‘very well met (n = 9, 45%), but the majority stated mental health needs were met only ‘somewhat (n = 5, 25%) or ‘a little bit/not at all (n = 6, 30%).

Conclusion: JM patients with positive mental health screening results did not often access timely mental health specialist follow-up. Barriers and facilitators, such as lack of mental health providers with experience with patients with JM and the role of pediatric rheumatologists in facilitating referral, were identified and replicate prior qualitative study findings. Given that respondents often endorsed unmet mental health needs and difficulty accessing mental health care, novel mental health care delivery approaches (e.g. integrated care) warrant further study to ensure appropriate mental health evaluation and treatment for JM patients.

Supporting image 1Table 1: Participant Descriptive Statistics

Supporting image 2Figure 1: Barriers to Mental Health Evaluation

Supporting image 3Figure 2: Facilitators for Addressing Mental Health


Disclosures: K. Ardalan: None; R. Fillipo: None; C. ZIgler: None; A. Ward: None; J. Dvergsten: None; A. Reed: None; A. Manning: None; G. Maslow: None; B. Feldman: None; A. Danguecan: None; S. Mossad: None; L. Flores Pereira: None; S. Shenoi: Novartis, 2, Pfizer, 1; S. Haynes: None; J. Patten: None; A. Knight: None.

To cite this abstract in AMA style:

Ardalan K, Fillipo R, ZIgler C, Ward A, Dvergsten J, Reed A, Manning A, Maslow G, Feldman B, Danguecan A, Mossad S, Flores Pereira L, Shenoi S, Haynes S, Patten J, Knight A. What Happens After Juvenile Myositis Patients Screen Positive for Mental Health Comorbidities? Update from a Multicenter Juvenile Myositis Mental Health Screening Pilot Study [abstract]. Arthritis Rheumatol. 2023; 75 (suppl 4). https://acrabstracts.org/abstract/what-happens-after-juvenile-myositis-patients-screen-positive-for-mental-health-comorbidities-update-from-a-multicenter-juvenile-myositis-mental-health-screening-pilot-study/. Accessed .
  • Tweet
  • Email
  • Print

« Back to 2023 Pediatric Rheumatology Symposium

ACR Meeting Abstracts - https://acrabstracts.org/abstract/what-happens-after-juvenile-myositis-patients-screen-positive-for-mental-health-comorbidities-update-from-a-multicenter-juvenile-myositis-mental-health-screening-pilot-study/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology